Neillove public
[search 0]

Download the App!

show episodes
 
Loading …
show series
 
The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 3: Biologic Rationale for and Available Data with PARP Inhibition in Combination with Chemotherapeutic and Immunotherapeutic Agents in the Management of Advanced Ovarian Cancer — Dr Moore. CME information and select publications…
 
Featuring a discussion on recent data with CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer with Prof Stephen Johnston, including the following topics: Management of Localized ER-Positive, HER2-Negative Early Breast Cancer: Recent Advances in Adjuvant Systemic Endocrine-Based Therapies — Stephen Johnston, MA, PhD (0:00) Case: A p…
 
Featuring a roundtable discussion with Drs Scott Kopetz, Wells A Messersmith and Alan P Venook on the following topics: Biomarkers in Metastatic Colorectal Cancer (mCRC) Case: A man in his mid-20s with microsatellite instability (MSI)-high metastatic adenocarcinoma of the colon and ROS1 deletion experiences a complete response with ceritinib on a c…
 
Proceedings from a live CME webinar during the virtual IASLC 2020 North America Conference on Lung Cancer. Featuring perspectives from Drs Roy S Herbst, Suresh S Ramalingam and Helena Yu on the following topics: Introduction (0:00) Overview of EGFR tumor mutations; selection of first-line therapy (1:20) First-line treatment of NSCLC with EGFR mutat…
 
Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Johanna Bendell, Crystal Denlinger, and Axel Grothey on the following topics: Introduction (0:00) BRAF-Mutated Colorectal Cancer (2:16) Checkpoint Inhibitors in Colorectal and Gastroesophageal Cancer (30:00) HER2-Positi…
 
Featuring a discussion on recent data on the treatment of non-small cell lung cancer with ALK and ROS rearrangements with Dr Ross Camidge, including the following topics: Management of NSCLC with ALK or ROS1 rearrangements (0:00) Therapeutic approach to metastatic NSCLC with ALK rearrangements in the first-line setting (23:15) Case: A man in his mi…
 
Featuring perspectives from Dr Jennifer Woyach on the following topics: Practical considerations in treatment of CLL for practicing clinicians — Jennifer Woyach, MD (0:00) Case: A man in his early 60s with CLL with an IGHV mutation and deletion 13q receives ibrutinib/obinutuzumab on the control arm of the ECOG-EA9161 trial (26:25) Case: A man in hi…
 
Loading …

Quick Reference Guide

Copyright 2020 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login